Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Verekitug (UPB-101) in Adults with Severe Asthma
2024-519469-23-00Phase 2Authorised
- Sponsor
- Upstream Bio
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 2, open-label trial of vereckitug in severe asthma (2 arms), sponsored by Upstream Bio. Planned start Aug 2025; status: authorised.
02
Drugs
vereckitug
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2024-519469-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519469-23-00.